Cholesterol levels improve with weight loss and healthy fat-rich diet

A University of California, San Diego School of Medicine study finds that weight loss programs that provide healthy fats, such as olive oil in the Mediterranean diet, or a low-fat, high-carbohydrate diet have similar impacts on pound-shedding. More specifically, the researchers report that a meal plan rich in walnuts, which are high in polyunsaturated fats, has a significant impact on lipid levels for women, especially those who are insulin-resistant.

In the United States, 28 percent of adults over 40 of age use lipid-lowering drugs. Lifestyle changes that promote weight loss and reducing consumption of saturated fat have been associated with reducing levels of "bad" cholesterol, but a question persisted: Should consumers reduce fat intake by replacing with carbohydrates or substitute unsaturated fats for saturated fats?

"Many diets have said it is okay to eat healthy fats and emphasize olive and canola oils," said Cheryl Rock, PhD, principal investigator of the study, published this week in the Journal of the American Heart Association. "What we found is that a diet high in healthy oils did lower lipids, but it also lowered both good and bad cholesterol."

Overweight and obese adult women were enrolled in a one-year behavioral weight loss program and randomly assigned to one of three diets consisting of either: low-fat and high-carbohydrate; low-carbohydrate and high-fat; or a walnut-rich, high-fat and low-carbohydrate diet.

The findings showed that all three dietary plans promoted similar weight loss. Insulin-sensitive women lost the most weight with a low-fat diet but that strategy did not result in the most benefit for lipid levels.

The walnut-rich diet had the most impact on cholesterol levels by decreasing low-density lipoprotein (LDL), or bad cholesterol, and increasing beneficial high-density lipoprotein (HDL). The high-fat, low-carb group, which consumed monounsaturated fats, did not experience the same beneficial effects as the walnut-rich diet, which featured polyunsaturated fatty acids.

At six months, the average weight loss was almost 8 percent among all groups.

"This weight loss may not put these women at their ideal weight, but it made a significant reduction in their risk of cardiovascular and other diseases," said Rock. "This level of weight loss is achievable and can have a dramatic impact on their quality of life."

Insulin sensitivity was assessed in the study because people who are overweight usually have some degree of insulin resistance. Higher amounts of insulin are more likely to cause cells to lose their ability to regulate growth, a precursor to cancer.

"Diet composition impacts lipid levels, but the critical factor to lose weight continues to be to burn more calories than you consume," said Rock.

Additional study co-authors include Tran Le, Shirley W. Flatt, Loki Natarajan, Bilge Pakiz, Elizabeth L. Quintana, Dennis D. Heath, and Brinda K. Rana, UC San Diego.

This research was funded, in part, by the National Institutes of Health (CA155435) and the California Walnut Commission.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche purchases shares in tender offer for Ignyta…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares v...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]